ICCCImmuCell Corporation

$60M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+24.9% YoY

Gross Profit

$7M49.1% margin

Operating Income

-$954,000-7.0% margin

Net Income

-$1M-9.4% margin

EPS (Diluted)

$-0.19

Cash Flow

Operating Cash Flow

$233,511

Free Cash Flow

-$1M

Stock-Based Comp.

$313,144

Balance Sheet

Total Assets

$39M

Total Liabilities

$10M

Stockholders' Equity

$29M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$11M	+24.9%
Gross Profit	$7M	$5M	+29.8%
Operating Income	-$954,000	-$1M	+34.1%
Net Income	-$1M	-$2M	+44.2%

ICCC FY 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena